Non-small cell Lung Cancer
Conditions
Interventions
None listed
Sponsors
PHRF
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients diagnosed as having advanced or postoperative recurrent NSCLC prior to enrollment 2)Patients diagnosed as carrying activating EGFR mutation by each institution (exon19 deletion, exon 21 L858R mutation, or other minor mutations such as exon 18 G719X) 3)Those being treated without progression, or to be treated with, an EGFR-TKI as anticancer therapy 4)ECOG PS 0-2 5)20 years old over 6)Submitted signed informed consent
Exclusion criteria
Exclusion criteria: 1)Prior treatment with EGFR-TKI 2)HBsAg or HCV-RNA positive Patients 3)HIV positive Patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| *The plasma DNA T790M positivity rates by Cobas EGFR Mutation Test in the T790M positive tumors patients. *The plasma DNA T790M positivity rates at each clinical point. | — |
Secondary
| Measure | Time frame |
|---|---|
| *The plasma DNA EGFR Exon 19 deletion or Exon 21 L858 mutation positivety rates in clinical courses *Time from plasma T790 positivity to tissue T790M positivity in the tissue T790M-positive cases *Response Rate and PFS with Osimertinib *Response Rate and PFS with rechallenge of other EGFR-TKIs | — |
Countries
Japan
Contacts
Public ContactAkira Yamao
Public Health Reseach Foundation Comprehensive Support Project for Oncology Research
Outcome results
None listed